SCHEMBL182797

SCHEMBL182797

COc1ccc(-c2nc(N)nc3ccc(-c4cnc5ccccc5c4)cc23)cc1OC

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 3/20 0.73
PIK3CA P42336 3/20 0.73
PIK3CB P42338 2/20 0.73
MTOR P42345 2/20 0.73
PIK3CG P48736 2/20 0.73
PDGFRB P09619 4/20 0.52
PDGFRA P16234 4/20 0.52
ADORA1 P30542 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
ADORA2A P29274 3/20 0.47
AAK1 Q2M2I8 1/20 0.46
PDE10A Q9Y233 1/20 0.44
GAK O14976 2/20 0.43
KIT P10721 1/20 0.43
ACACA Q13085 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL182850 0.86 DHFR (0.53) PIK3CDPIK3CAPIK3CBMTORPIK3CG
SCHEMBL183330 0.84 PIK3CA (1.00) PIK3CDPIK3CAPIK3CBMTORPIK3CG
SCHEMBL183029 0.84 PIK3CA (0.51) PIK3CDPIK3CAPIK3CBMTORPIK3CG
SCHEMBL29377512 0.83 PIK3CD (0.73) PIK3CDPIK3CAPIK3CBMTORPIK3CG
SCHEMBL182901 0.83 PIK3CA (0.51) PIK3CDPIK3CAPIK3CBMTORPIK3CG
SCHEMBL182810 0.82 PIK3CA (0.49) PIK3CDPIK3CAPIK3CBMTORPIK3CG
SCHEMBL183022 0.80 SQSTM1 (0.48) PIK3CDPIK3CAPIK3CBMTORPIK3CG
SCHEMBL182874 0.79 PDGFRB (0.48) PIK3CDPIK3CAPIK3CBMTORPIK3CG
SCHEMBL182897 0.79 ADORA1 (0.48) PIK3CDPIK3CAPIK3CBMTORPIK3CG
SCHEMBL182575 0.79 ADORA1 (0.52) PIK3CDPIK3CAPIK3CBMTORPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP claimed
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors NOVARTIS AG 2009-10-15 US claimed
EP-2049502-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2009-04-22 EP claimed
WO-2008012326-A1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2008-01-31 WO claimed
EP-2049502-B1 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258882-A1 2,4-Substituted Quinazolines as Lipid Kinase Inhibitors PDPK1, PI4KA, PIK3CA PIK3CD 6/4885PIK3CA 3/4885PIK3CB 12/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.